Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Antiviral, and HIV Cure Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for APOBEC3H drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Enzyme WT | APOBEC3H Recombinant Protein (Full-length, Haplotype II). High purity (>95%), Sequence Verified. Expressed in HEK293/E.coli. Includes variant with rs139293 and allele A3H-Var. | View APOBEC3H Products |
| Catalytic Mutant | APOBEC3H H102A Mutant Protein. Catalytically inactive control for dominant negative and mechanistic studies. Endotoxin <1EU/µg. | View APOBEC3H Products |
| Stability Mutant | APOBEC3H mutant with decreased protein stability (UniProt VAR_065622). For functional studies on degradation pathways. | View APOBEC3H Products |
| Gene Delivery | APOBEC3H Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. CMV promoter, Puromycin selection. | View APOBEC3H Products |
| Detection Ab | Anti-APOBEC3H Rabbit mAb. Sequence Verified clone for Western Blot and IP applications. | View APOBEC3H Products |
| Validator | APOBEC3H siRNA Set (3 targets). For knockdown verification and specificity controls. | View APOBEC3H Products |
| Related Target A | APOBEC3B. Synergistic mutational signature target in solid tumors; critical for pan-APOBEC selectivity panels. | View APOBEC3B Products |
| Related Target B | APOBEC3G. HIV restriction factor; essential off-target counter-screening and viral evasion co-target. | View APOBEC3G Products |
| Related Target C | APOBEC3A. Highly active deaminase family member driving tumor evolution. | View APOBEC3A Products |
| Related Target D | APOBEC1. RNA editing control; specificity comparison studies. | View APOBEC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Haplotype Stability & Variance | Specific structural variants (e.g., Haplotype II) are Sequence Verified to guarantee accurate conformation. Includes rs139293 and high-expression allele. |
| Isoform Selectivity (Pan-APOBEC Counter Screening) | Homolog panel (A3A, A3B, A3C, A3D, A3F, A3G, A3H, APOBEC1) available with >95% purity, Mass Spec verified for cross-reactivity assays. |
| Catalytic vs. Non-catalytic Binding | Matched WT and H102A Mutant pair available for mechanistic deconvolution (SPR, DSF). |
| Cellular Target Engagement & Reporter Assays | Lentiviral ORF particles for stable integration into reporter cell lines (HEK293T, Jurkat). Validated siRNA included for absolute specificity checks. |
| Substrate Oligomerization State Integrity | HEK293 Expression System ensuring native folding and proper dimer/tetramer formation essential for activity. |
Global Clinical Landscape & Future Outlook
The race for APOBEC3H-targeted therapeutics is intensifying, representing a paradigm shift in oncology and virology. Traditionally recognized for its role in restricting HIV-1 (counteracted by viral Vif), APOBEC3H is now heavily implicated in the "APOBEC mutational signature" driving tumor evolution and drug resistance. As first-generation targeted therapies (e.g., kinase inhibitors) face resistance, the next wave of R&D targets intracellular deaminases like APOBEC3H to suppress adaptive mutagenesis—effectively "freezing" tumor evolution. Modalities are shifting toward small molecule inhibitors, PROTACs, and genetic modulators designed for the intracellular environment. Pan-APOBEC inhibitors that simultaneously block A3B and A3H are emerging as a key strategy to prevent compensatory resistance. In HIV, degradation of APOBEC3H via PROTAC may overcome the limitations of "shock and kill" approaches. Critical assay needs include isoform-selective enzymatic panels, haplotype-specific reagents (e.g., Haplotype II), and cellular reporter systems.
Key Mutations and Functional Domains
APOBEC3H contains a CMP/dCMP-type deaminase domain (UniProt Q6NTF7). Key mutations:
- Decreases protein stability (UniProt VAR_065622) – useful for stability/ degradation studies.
- rs139293 (dbSNP, UniProt VAR_032835) – common variant in population.
- Allele A3H-Var; Haplotype 2 (UniProt VAR_032836) – confers higher expression and stability; essential for accurate drug screening.
TarMart provides recombinant wild-type (Haplotype II), catalytic dead (H102A), stability mutants, and the high-expression variant to support mechanistic and selectivity studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic consortia, Emerging biotechs | Solid tumors (mutagenesis prevention), HIV-1 | Enzymatic Activity Assay (Need high-purity WT, H102A, and haplotype variants) |
| PROTAC Degrader | Therapeutic discovery platforms | HIV reservoir persistence, refractory cancers | Cellular Turnover Assay (Need lentivirus for stable A3H overexpression and matched mutant controls) |
| Allosteric Modulator/Activator | Virology institutes | Antiviral enhancement | Conformational Binding Assay (Need native-folded, tag-minimized proteins from HEK293) |
| Gene Therapy / RNAi / CRISPR | Preclinical gene therapy labs | Infectious disease, inherited immunity | Knockdown Validation (Need validated siRNA, lentiviral ORF, and A3 family protein panel for off-target screening) |
Live APOBEC3H R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: